Indaptus Therapeutics Inc (INDP NASDAQ) stock market data APIs
$2.3601
0.06(2.5%)
as of September 17, 2025
Try our APIs with
free plan!
Indaptus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Prev. Close
2.3601
Open
2.4161
High
2.4161
Low
2.262
52 wk Range
2.22-58.24
Market Cap
2 667 K
Shares Outstanding
1 107 K
EPS
-9.09
Beta
1.132
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Indaptus Therapeutics Inc data using free add-ons & libraries
Get Indaptus Therapeutics Inc Fundamental Data
Indaptus Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 342 581
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Indaptus Therapeutics Inc News
New
Indaptus Therapeutics Provides Clinical Update
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with...
Indaptus Therapeutics GAAP EPS of -$9.09
* Indaptus Therapeutics press release [https://seekingalpha.com/pr/20199347-indaptus-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:INDP [https://seekinga...
Indaptus Therapeutics raises $5.7 million through convertible notes
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), whose stock has declined over 80% in the past year and currently trades at $10.53, announced Tuesday it has raised an additional $3.4 million thro...
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral in...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
